aTyr Pharma

ATYR · NASDAQ

$0.1733+$0.0016 (+0.93%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.1717

ATYR analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 8 analysts

Average $2.89 (+1567.6% upside)

Low: $1.01
Now: $0.1733
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

ATYR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Freedom Broker	May 20, 2026	Upgrade	Hold → Buy	$1.00 → $3.50	45%
RBC Capital	Nov 7, 2025	Maintains	Sector Perform	$1.50 → $1.00	44%

The case for and against

Updated Feb 9, 2026

Bull case

aTyr Pharma Inc. demonstrates a positive outlook due to the promising results from its Phase II clinical trial of efzofitimod, which showed not only the potential to spare steroid use but also achieved meaningful improvements in lung function within 24 weeks. Furthermore, interim results indicated significant enhancements in modified Rodnan skin score (mRSS) for patients with diffuse systemic sclerosis, underscoring the drug's efficacy in addressing complex fibrotic conditions. The company's strategic focus on expanding indications for efzofitimod and other candidates in its pipeline presents considerable upside potential that could enhance market valuation.

Bear case

aTyr Pharma Inc faces a negative outlook primarily due to recent clinical setbacks related to its product candidate, efzofitimod, which has significantly reduced the projected revenue opportunity in pulmonary sarcoidosis (PS) to less than $300 million. Furthermore, there are increasing concerns surrounding potential developmental hurdles, such as unexpected safety signals and the possibility of failing to secure regulatory approval, which could lead to substantial downward revisions in financial estimates. Although there is some indication of potential drug activity in systemic sclerosis-associated interstitial lung disease (SSc-ILD), the study failure in PS adds an additional layer of risk, further dampening confidence in the company's future financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.